We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. ×
Market Research Report

Analysis of Global Chronic Kidney Disease (CKD) Drugs Market by Drug Class and Distribution Channel with Regional Outlook and forecast to 2025

Published Date :


Report Pages :


Format :


Region Covered :


Market Outlook

Kidneys have vital role in discarding the waste from body, blood regulation and mineral homeostasis. Dysfunction of the kidney leads to chronic kidney disease and has adverse impact on rest of the body. The factors such as increasing geriatric population, rise in number of chronic kidney disease cases and prevalence of other disease in body (such as diabetes, high blood pressure, smoking, obesity and others) that risk the increase of chronic kidney disease (CKD), tends to drive the global chronic kidney disease drugs market.

In current scenario, there are no drugs/medications that can cure or reverse the effect of CKD but by controlling and curing other diseases such as high blood pressure, diabetes, anemia and others can help to treat the symptoms. Various pharmaceutical companies are researching to find drugs and better treatment process of CKD. One such example is Novadiol, a pharmaceutical company, is undergoing the clinical trials of Dendocrin to treat secondary hyperparathyroidism (SHPT) in stage 3 and 4 CKD patients.

Market Insights

Demand for Chronic Kidney Disease Drugs in Brazil Buoyed by Increasing no of Patients Suffering from Renal Disorders

In the United States nearly 20 million people are suffering from kidney disorders and 600,000 have kidney failure. Whereas in Brazil, 10 million people are identified to suffer from renal disorders and this incidence is growing at a rate of 10.0% every year, which is thus inducing the demand for chronic kidney disease drugs.

High Growth Opportunities in Terms of Supply of CKD Drugs in North America and Latin America

As per the research, major etiology of CKD is hypertension (80.0%) presented in patients followed by diabetes (33.0%) and cardiovascular diseases (11.9%) patients. The incidences of hypertension is increasing across the world including developed and developing countries. Therefore, the countries with increasing rate of diseases have higher rate CKD cases amounting to rise in demand of CKD drugs. The pharmaceutical companies and distribution companies have high growth opportunities in terms of supply of CKD drugs in the regions with rise in number of cases that are causing CKD, such as North America & Latin America.

Chronic Kidney Disease (CKD) Drugs Market Segmentation

Our Global Chronic Kidney Disease Drugs Market can be segmented on the following basis:

Based on Drug Class

  • ACE Inhibitors
  • Calcium Channel Blockers
  • Beta Blockers
  • Angiotensin-II Receptor Blockers
  • Diuretics
  • Others (Erythropoiesis – stimulating Agents (ESAs))

Based on Distribution Channel 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on Geography 

  • North America (U.S. & Canada)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
  • Latin America (Brazil, Mexico & Rest Of Latin America)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
  • Europe (The U.K., Germany, France, Italy, Hungary, Spain, Poland, Sweden & Roe)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest Of Asia)  Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}
  • Middle East & Africa (GCC, South Africa, North Africa, Romea) Chronic Kidney Disease Drugs Market {Market Share (%), Market Size (USD Billion)}

Factors covered in this study on CKD drugs market:

  • Market statistics such as size (USD), market share (%) and market growth CAGR (%) & forecast for 2017-2025 based on segmentation by drug class, by distribution channel and by region 
  • Chronic kidney disease drugs under pipeline
  • Number of new cases diagnosed of chronic kidney disease
  • In-depth competitive analysis of the major players and leaders in Moroccan Home Appliances Market.
  • Present ground scenario and future opportunity prospects for the market players to analyze the target markets across the globe.
  • The report also includes porter’s five force model, market attractiveness, SWOT analysis, corporate profiling, business strategies of market players and their business models.
  • Morocco Home Appliances Market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.
  • To understand the market dynamics, the report discusses the growth factors, challenges, risk analysis, trends & opportunities in the market for the new & existing players.

Some of the major players included in the chronic kidney disease drugs market report are: Amgen Inc., Pfizer Inc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., and Keryx Biopharmaceuticals Inc.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.

For a detailed overview send us request for CKD market report sample.




{ }

Analysis of Global Chronic Kidney Disease (CKD) Drugs Market by Drug Class and Distribution Channel with Regional Outlook and forecast to 2025

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

Table of Contents

Please Select Linenece Type